SynthesisFrontiers in medicine2021
Role of Clofazimine in Treatment of
Synthesis in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Clofazimine against cerebral toxoplasmosis in diabetic and dexamethasone-immunosuppressed mice: ultrastructural and semiquantitative transmission electron microscopic study.BMC neuroscience · 2026Article
- Observational
- Treatment strategies forBreathe (Sheffield, England) · 2026Article
- Recent advances in immunopathogenesis and clinical practice: mastering the challenge-managing of non-tuberculous mycobacteria.Frontiers in immunology · 2025Review
- Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?Antimicrobial agents and chemotherapy · 2024Article
- Article
- Encapsulation of Clofazimine by Cyclodextran: Preparation, Characterization, and In Vitro Release Properties.International journal of molecular sciences · 2023Article
- Improving the Antimycobacterial Drug Clofazimine through Formation of Organic Salts by Combination with Fluoroquinolones.International journal of molecular sciences · 2023Article
- Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.Respiratory research · 2022Review
- In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.BMC microbiology · 2022Article
- Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.